GSK has announced positive headline outcomes from a Phase III trial of Blenrep with bortezomib and dexamethasone for multiple ...

GSK's phase 3 trial shows Blenrep combined with BorDex improves overall survival in relapsed multiple myeloma.

In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...

European patent related to an inhaler revoked following successful appeal by GSK | Ruling comes after a series of challenges over novelty and inventive step | Decision further intensifies ongoing ...

Clinical study reports for the FURI, CARES and NATURE trials in refractory or resistant invasive fungal infections were delivered to GSK, ...

GSK cut its full-year vaccine sales outlook after key shots for respiratory syncytial virus and shingles missed expectations ...

RSV is a highly contagious virus that spreads through close contact with infected individuals ... That's why the American Lung Association, with support from GlaxoSmithKline, is encouraging adults at ...

In a strategic move to enhance their immunology portfolio, GSK has announced an agreement to acquire experimental therapy CMG1A46 from Chimagen Biosciences, a privately-held biotechnology company ...

GSK is on track to achieve its guidance for 2024, with its Q3 2024 and 9m 2024 results today. For 9m 2024, the company's turnover growth at 9% is at the upper end of the guidance range and core ...

GSK GSK-1.51%decrease; red down pointing triangle cut its full-year vaccine sales outlook after key shots for respiratory syncytial virus and shingles missed expectations in the third quarter due ...